Oyavas (Bevacizumab)

Oyavas is a VEGF‑targeting therapy used in several oncology indications where angiogenesis drives disease progression.

• Colorectal cancer: improves survival when combined with chemotherapy in metastatic disease.
• Non‑small cell lung cancer: enhances response rates in combination regimens for advanced disease.
• Glioblastoma multiforme: prolongs progression‑free interval when added to radiotherapy.
• Ovarian cancer: increases progression‑free survival in recurrent disease.
• Cervical cancer: used with chemotherapy for persistent, recurrent or metastatic tumours.
• Renal cell carcinoma: part of combination protocols for advanced disease.

• Bevacizumab binds selectively to vascular endothelial growth factor A (VEGF‑A), preventing it from activating its receptors on endothelial cells. This inhibition blocks new blood‑vessel formation (angiogenesis), limiting tumour blood supply, reducing nutrient delivery, and ultimately slowing tumour growth and metastasis.

Adverse reactions to bevacizumab vary from mild to severe and are monitored throughout therapy.

Common Side Effects

• Hypertension: elevated blood pressure requiring medical management.
• Proteinuria: presence of protein in urine, often transient.
• Bleeding: epistaxis, gum bleeding or minor bruising.
• Wound healing complications: delayed closure after surgery.
• Fatigue: generalised tiredness reported by patients.
• Gastrointestinal perforation: rare abdominal pain with signs of peritonitis.

Serious or Rare Side Effects

• Arterial thromboembolism: risk of heart attack or stroke.
• Severe hemorrhage: gastrointestinal or intracranial bleeding.
• Severe wound dehiscence: postoperative wound breakdown.
• Nephrotic syndrome: significant protein loss leading to swelling.
• Posterior reversible encephalopathy syndrome (PRES): neurological changes with imaging findings.
• Fatal infusion reactions: anaphylaxis or severe hypersensitivity.

Bevacizumab requires careful monitoring and specific safety measures before and during treatment.

• Blood pressure monitoring: check and control hypertension before each infusion.
• Renal function assessment: evaluate proteinuria and kidney health regularly.
• Bleeding risk assessment: review patient history of hemorrhage or anticoagulant use.
• Surgical planning: avoid elective surgery within 28 days of the last dose.
• Pregnancy and lactation: contraindicated; avoid use in pregnant or nursing women.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Bevacizumab may interact with several drug classes, influencing safety and efficacy.

Major Interactions (Avoid)

• Anticoagulants: increased risk of severe bleeding.
• Antiplatelet agents: heightened hemorrhagic potential.
• High‑dose aspirin: may exacerbate bleeding complications.

Moderate Interactions (Monitor Closely)

• Chemotherapy agents (e.g., paclitaxel, carboplatin): may enhance toxicities.
• Hypertensive agents: require dose adjustments to control blood pressure.
• NSAIDs: can worsen renal impairment and proteinuria.